Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
where to buy fat dildos? - LovToyLand.com
Popular Articles

46 R&D 100 Awards For 2009 Won By DOE-Funded Research Projects
U.S. Secretary of Energy Steven Chu has announced that Energy Department-funded researchers have won 46 of the 100 awards given out this year by R&D Magazine for the most outstanding technology developments with promising commercial potential. The coveted awards are presented annually in recognition of exceptional new products, processes, materials or software developed throughout the world and introduced into the market the previous year.
diet pills
From Oxygen Transport To Melanin Formation: Activation Mechanism Of Key Enzymes Explained
Pandinus imperator, the emperor scorpion, is not only popular as a pet, but is also of interest for research purposes. The reason for this is its blue blood, which transports oxygen and distributes it throughout the body. Like tyrosinase, the key enzyme in melanin synthesis, the blue blood pigment hemocyanin found in the emperor scorpion and other arthropods belongs to a group of special molecules that occur in all organisms and that have many different functions: coloring the skin, hair and eyes, immune response, wound healing or the brown discoloration of fruit. "When these enzymes mutate, this may result in albinism, or in birth marks when production of the pigment melanin increases, as often seen in melanoma," explains Professor Heinz Decker of Johannes Gutenberg University Mainz. The biophysicist has been studying hemocyanins and the associated tyrosinases for the past 20 years. In cooperation with researchers, Dr. Cong and Dr. Chiu, from the Baylor College of Medicine in Houston he has now been able to show for the first time exactly how the enzymes become active, thereby fulfilling their various functions. This work was published in the journal Structure on 13 May.
News of the day
BioElectronics Provides Clinical Study Data; Company To File Comprehensive FDA Application For OTC Clearance For Musculoskeletal Complaints
BioElectronics Corp. (PINKSHEETS: BIEL), the maker of inexpensive, disposable drug-free anti-inflammatory devices, held a conference call yesterday morning, a replay of which is available by dialing (888) 203-1112 and entering passcode 4461002.
Diagnostics

CHMP Recommends Expanded Use Of ISENTRESS(R) (Raltegravir), From MSD, In Adult Patients With HIV-1 Infection

Merck Sharp & Dohme Limited (MSD) received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending expanded marketing authorisation for "Isentress" (raltegravir) in combination with other antiretroviral (ARV) medicinal products for the treatment of HIV-1 infection in all appropriate adult patients, including patients starting HIV therapy for the first time (treatment-naç¯ve), as well as treatment-experienced patients. The positive opinion will be reviewed by the European Commission, which grants marketing authorisation to the 27 countries that are members of the European Union (EU), as well as Iceland and Norway. Raltegravir, the first and only approved integrase inhibitor, is currently approved in more than 80 countries across six continents for use in combination with other ARV agents for the treatment of HIV-1 infection in treatment-experienced adult patients with evidence of HIV-1 replication despite ongoing ARV therapy1. If marketing authorisation is granted by the European Commission, the drug will be approved for use both in treatment-naç¯ve and treatment-experienced patients. About Raltegravir Raltegravir works by inhibiting the insertion of HIV-1 DNA into human DNA by the integrase enzyme and has demonstrated rapid antiviral activity2. Inhibiting integrase from performing this essential function limits the ability of the virus to replicate and infect new cells2. There are drugs in use that inhibit two other enzymes critical to the HIV-1 replication process - protease and reverse transcriptase - but raltegravir is the only drug approved that inhibits the integrase enzyme3. Raltegravir is a single 400 mg tablet taken twice daily without regard to food. Raltegravir does not require boosting with ritonavir1. References 1. Summary of Product Characteristics 2. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and Efficacy of the HIV-1 Integrase Inhibitor Raltegravir (MK-0518) in Treatment-Experienced Patients with Multidrug-Resistant Virus: A Phase II Randomised Controlled Trial. The Lancet 2007; 369:1261-1269. 3. Hazuda DJ, Felock P, Witmer M, et al. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000; 287:646-50. Merck Sharp & Dohme Limited


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009